SCHEMBL7723655

SCHEMBL7723655

[111In]

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7203790 0.71
Hydrochloric Acid SCHEMBL3488899 0.71
Methane SCHEMBL23088734 0.00
Hydrogen Sulfide SCHEMBL23805181 0.00
SCHEMBL23528133 0.00
SCHEMBL23462252 0.00
SCHEMBL25435013 0.00
SCHEMBL23462141 0.00
Potassium Ion SCHEMBL23462035 0.00 CA4 (0.50)
SCHEMBL23358113 0.00

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 5747 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122094718-A Image-guided biopsy of HER2 positive lesions 2026-05-26 CN claimed
US-20260137821-A1 PEPTIDE STRUCTURE TARGETING CARBONIC DEHYDROGENASE IX AND USE THEREOF C-BIOMEX CO., LTD. (KR) 2026-05-21 US claimed
EP-4211146-B1 SYNTHETIC CYCLIC PEPTIDE MIMETICS UNIV BAR ILAN (IL) 2026-05-20 EP claimed
EP-4743489-A1 HUMANISED ANTIBODIES AND USES THEREOF Telix Pharmaceuticals (Innovations) Pty Ltd (AU) 2026-05-20 EP claimed
WO-2026098441-A1 COMPOSITION AND METHOD FOR CANCER TREATMENT USING POLYPEPTIDE CONJUGATES SUZHOU SMARTNUCLIDE BIOPHARMACEUTICAL CO., LTD. (CN) 2026-05-15 WO claimed
WO-2026099761-A1 PEPTIDES SALEM YAHYA AHMED (EG) 2026-05-15 WO claimed
EP-4736841-A1 A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT IQ medical GmbH (DE) 2026-05-06 EP claimed
US-12616760-B2 Synthetic cyclic peptide mimetics BAR ILAN UNIVERSITY (IL) 2026-05-05 US claimed
US-20260115332-A1 Fibroblast Activation Protein Alpha-Cleavable Pro-Peptides and Methods of Use UNIV CALIFORNIA (US) 2026-04-30 US claimed
US-20260103519-A1 BISPECIFIC, MODULATABLE ANTIBODY OR ANTIGEN BINDING FRAGMENTS THEREOF IBIO INC (US) 2026-04-16 US claimed
US-20220111081-A1 COMPOSITION FOR TARGETING MEDULLARY THYROID CANCER University-Industry Foundation, Yonsei University (KR) 2022-04-14 US claimed
EP-3976542-A1 RADIOPAQUE GLASS MATERIAL ABK Biomedical Incorporated (CA) 2022-04-06 EP claimed
US-20220098613-A1 REDUCING CD33 EXPRESSION TO SELECTIVELY PROTECT THERAPEUTIC CELLS FRED HUTCHINSON CANCER RESEARCH CENTER (US) 2022-03-31 US claimed
US-20220096646-A1 SSTR-TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF TVA (ABC), LLC 2022-03-31 US claimed
EP-3247727-B1 INHIBITORS OF THE INTERACTION BETWEEN CLEC14A AND MULTIMERIN-2 FOR INHIBITION OF ANGIOGENESIS CANCER RESEARCH TECH LTD (GB) 2022-03-23 EP claimed
CN-114206796-A Radiopaque glass material ABK生物医学公司 2022-03-18 CN claimed
WO-2022053651-A2 ANTIBODY FRAGMENT AGAINST FAP PRECIRIX N.V. (BE) 2022-03-17 WO claimed
EP-3948284-A1 METHODS, ARRAYS AND USES THEREOF FOR DIAGNOSING OR DETECTING AN AUTOIMMUNE DISEASE Immunovia AB (SE) 2022-02-09 EP claimed
CN-108473538-B SSTR targeting conjugates and particles and formulations thereof 塔弗达治疗有限公司 2022-01-28 CN claimed
US-20220026411-A1 ANALYTICAL METHODS AND ARRAYS FOR USE IN THE SAME SENZAGEN AB (SE) 2022-01-27 US claimed